Boston, USA-based Newleos Therapeutics, a neuroscience company co-founded by Longwood Fund and seasoned leaders in CNS drug ...

Newleos Therapeutics Inc. was created by the Longwood Fund along with CNS drug developers Federico Bolognani and William Martin. The startup’s clinical-stage pipeline was licensed from Roche and ...

Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company with a market capitalization of $5.2 billion focused on developing novel therapies for central nervous system (CNS) disorders, has ...

For decades, scientists across the globe have investigated methods to accurately measure drug permeability across the blood-brain barrier, a compact layer of cells that protect the brain from ...

The 2022 National Survey on Drug Use and Health found that ... Stimulants increase CNS activity and can temporarily make someone feel more alert, energized, or confident. Learn signs that someone ...

In the first case, a special court for the Control of Narcotic Substances (CNS) in Attock sentenced to 9 years’ rigorous imprisonment (RI), besides imposing a fine on a drug peddler who was ...

Irritable bowel syndrome (IBS) is a common digestive disorder that affects the intestine, causing symptoms such as abdominal pain, bloating, gas, and changes in bowel habits, including diarrhea, ...

In Dec 2021, the moving annual total (MAT) sales for neuro-CNS drugs stood at Rs 456 ... Pharmarack data suggests that anti-epileptic drugs (30.7%), anti-depressants and mood elevator drugs ...

Private equity firm Bain Capital (BCSF) is paying $3.4 billion to buy a 350-year-old Japanese drugs group fighting diabetes ...